The Board of Directors of Artgen Biotech (MOEX: ABIO) approved the updated development strategy of the company, including for 2024-2026 goals to expand the development portfolio and create a production site for the development of the company’s ecosystem.
A long-term goal of "creating a cure for old age" (focusing on age-associated diseases) and two new goals, the implementation of which in the 2024-2026 period will lay the foundation for the dynamic development of the company in subsequent years, were added to the strategy:
These goals will complement the previously approved ones aimed at increasing financial performance in 2024-2026. It is about the development of already registered elaborations or those elaborations at advanced stages that are close to obtaining a market authorizetion:
Sergey Masyuk, Director of Artgen Biotech, said, "The company’s ecosystem accelerates biotech startups and helps group companies develop drugs from an idea to a drug prototype and its subsequent commercialization. Artgen Biotech plans to support up to 30 early developments of innovative drugs from molecular design to proof of concept in animal models. Of these, by 2026 it is planned to obtain 10 candidate drugs for the subsequent launch of 5-6 drugs on the market, among which 1 to 3 blockbuster drugs are expected."
New developments will be aimed at the treatment and prevention of diseases such as:
In the long-term strategy of Artgen Biotech, a focus was added on the creation of "medicines for old age" and the creation of the production part of the Artgen Biotech ecosystem.
Artur Isaev, Artgen Biotech founder, said, "A cure for old age is one of the formulas of our strategy and one of the principles for selecting specific developments. Some genetic diseases have pathogenetic mechanisms important for aging. It is precisely these mechanisms that we aim to influence. If we manage to influence them effectively, then there is a good chance that our drugs will have age-related diseases as indications for use. Gene therapy drugs for the treatment of orphan diseases, on which we are focused, are, in fact, the first step towards the development of drugs for the prevention and treatment of age-related diseases. This is an important task - to prevent or delay the development of age-associated diseases and thereby significantly extend the period of a person’s active life without serious illnesses."
The limiting factor on the path of biotech drugs to the market is the lack of specialized production. Until 2026, Artgen Biotech plans to expand the capabilities of its ecosystem and lay the conditions for startups to create licensed pilot production of drugs, for registered developments and drugs in the process of obtaining market authorizations".
Artgen Biotech is a biotechnology company with a portfolio of innovative platform developments to implement in healthcare. The Artgen Biotech group includes companies at different stages of development - from the seed stage to the stage of early growth and maturity, as well as companies that form an ecosystem for accelerating biotech developments in the group.